Mike Reed, PhDback to Management Team>

Vice President, Research and Development

As Vice President, Dr. Reed is responsible for managing strategic client collaborations. His experience in applying mathematical models to product development has given him unique insight into the difficult issues faced by biotechnology, pharmaceutical, and consumer product companies. In model development, he established rapport with clients to facilitate mutual knowledge exchanges in metabolic disease areas. Mike’s previous work in preclinical pharmacology and drug development moved him into lead positions for evaluating the safety and efficacy of candidates in animal models of various diseases. Apart from metabolic diseases, his background also includes rheumatoid arthritis, antibacterials, nutrition, exercise physiology, and pediatric and animal health.

Before joining Rosa, Dr. Reed was the Associate Director of Research and Development at Entelos, Inc., where he led the development of large-scale biosimulation models for the pharmaceutical industry. In that position, he managed a department of modelers and scientists who provided systematic analyses to support decisions in scientific interpretation and program direction in multiple therapeutic areas with pharmaceutical, biotechnology, and consumer product customers. These mathematical models provided insight and efficiency in clinical trial design, target identification and prioritization, competitive differentiation, and novel biomarker identification. Dr. Reed also led teams in the initial development of Metabolic Disease models in new therapeutic areas and patented novel biological IP arising from modeling. His work has been presented at multiple systems biology and diabetes conferences.

Prior to his position at Entelos, Mike held positions of increasing responsibility in preclinical pharmacology and drug development at Shaman Pharmaceuticals and Tularik. His responsibilities included leading teams that evaluated the efficacy and safety in animal models of preclinical candidate compounds for type 2 diabetes, obesity and bacterial infection. In addition, he developed novel animal models for type 2 diabetes to improve the translation of preclinical results to human predictions.

Dr. Reed completed his B.S. degree in Biology and his M.A. degree in Exercise Physiology at The University of Texas at Austin and attained a Ph.D. in Exercise Physiology at The Ohio State University, where his research focused on the effect of muscle contraction on skeletal muscle insulin resistance. Following his Ph.D., Dr. Reed completed a post-doctoral fellowship at Stanford University with Dr. Gerald Reaven, focusing on the mechanistic evaluation of insulin resistance in animal models of type 2 diabetes.

Dr. Reed’s hobbies include bicycle racing, soccer, cooking and playing the guitar.